Elevated hepatic iron: a confounding factor in chronic hepatitis C

Harriet C Isom1, Emily I McDevitt, Mi Sun Moon

  • 1Department of Microbiology and Immunology, The Pennsylvania State College of Medicine, Hershey, PA 17033, USA. hisom@psu.edu

Insights

Iron overload in the liver, linked to hereditary hemochromatosis and hepatitis C virus (HCV) infection, causes cellular damage and altered growth. Further research is needed to understand these complex molecular changes in the liver.

Area of Science:

  • Hepatology
  • Molecular Biology
  • Virology

Background:

  • Elevated hepatic iron is historically linked to hereditary hemochromatosis and thalassemia.
  • Chronic hepatitis C virus (HCV) infection is increasingly associated with elevated liver iron levels.
  • Both iron overload and HCV infection induce significant cellular stress and dysfunction in hepatocytes.

Purpose of the Study:

  • To investigate the molecular and cellular changes in the liver resulting from the co-occurrence of elevated hepatic iron and ongoing HCV replication.
  • To elucidate the clinical relevance of understanding these intertwined pathological processes.

Main Methods:

  • This study is a review and synthesis of existing research on iron metabolism and HCV pathogenesis.
  • Analysis of molecular pathways affected by both iron overload and HCV infection, including oxidative stress, endoplasmic reticulum stress, and mitochondrial dysfunction.

Main Results:

  • Iron overload induces oxidative stress, lysosomal and mitochondrial damage, and stimulates hepatocyte proliferation.
  • HCV infection triggers endoplasmic reticulum stress, unfolded protein response, oxidative stress, mitochondrial dysfunction, and altered growth control.
  • The interplay between iron overload and HCV leads to a complex cellular environment with potential for significant liver damage.

Conclusions:

  • Understanding the combined effects of iron overload and HCV infection on liver cells is crucial for clinical management.
  • Further research is warranted to fully elucidate the molecular mechanisms and therapeutic targets in livers affected by both conditions.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...